In vitro interactions of micafungin with amphotericin B against clinical isolates of Candida spp.
The in vitro activity of amphotericin B in combination with micafungin was evaluated against 115 isolates representing seven species of Candida. Overall, the percentages of synergistic interactions were 50% and 20% when the MIC-2 (lowest drug concentration to cause a prominent reduction in growth) and MIC-0 (lowest drug concentration to cause 100% growth inhibition) end point criteria, respectively, were used. Antagonism was not observed. Some of the interactions were confirmed by time-kill assays.
Serena
Carolina
C
Unitat de Microbiologia, Facultat de Medicina i Ciències de la Salut, Universitat Rovira i Virgili, Carrer Sant Llorenç, 21.43201 Reus, Spain.
Mariné
Marçal
M
Quindós
Guillermo
G
Carrillo
Alfonso J
AJ
Cano
J F
JF
Pastor
F Javier
FJ
Guarro
Josep
J
D000666:Amphotericin B / Q000494:pharmacology*; D000935:Antifungal Agents / Q000494:pharmacology*; D002175:Candida / Q000145:classification* / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D054714:Echinocandins / Q000494:pharmacology*; D006801:Humans; D055666:Lipopeptides; D008074:Lipoproteins / Q000494:pharmacology*; D000077551:Micafungin; D008826:Microbial Sensitivity Tests
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D008074:Lipoproteins; D000666:Amphotericin B; D000077551:Micafungin